chronic thromboembolic pulmonary hypertension
Cardiovascular · 2014–2016
3decisions
1medicine
3carried consumer input
16individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| riociguat Treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent CTEPH subsequent to pulmonary endarterectomy (PEA) in adult… | Mar 2016 | Recommended with restriction | 1 individuals |
| riociguat Treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent CTEPH subsequent to pulmonary endarterectomy (PEA). | Jul 2015 | Not recommended | 12 individuals |
| riociguat Treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary endarterectomy in patients with WHO… | Nov 2014 | Not recommended | 3 individuals Pulmonary Hypertension Association Australia |
Who spoke
Pulmonary Hypertension Association Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.